Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58


Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation.

Prado SBRD, Ferreira GF, Harazono Y, Shiga TM, Raz A, Carpita NC, Fabi JP.

Sci Rep. 2017 Nov 29;7(1):16564. doi: 10.1038/s41598-017-16709-3.


Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis.

Tang L, Li X, Gao Y, Chen L, Gu L, Chen J, Lyu X, Zhang Y, Zhang X.

PLoS One. 2017 Jul 3;12(7):e0179437. doi: 10.1371/journal.pone.0179437. eCollection 2017. Review.


IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.

Rohena-Rivera K, Sánchez-Vázquez MM, Aponte-Colón DA, Forestier-Román IS, Quintero-Aguiló ME, Martínez-Ferrer M.

PLoS One. 2017 Apr 5;12(4):e0172786. doi: 10.1371/journal.pone.0172786. eCollection 2017.


Prostate Cancer Genetics: A Review.

Wallis CJ, Nam RK.

EJIFCC. 2015 Mar 10;26(2):79-91. eCollection 2015 Mar.


DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.

Liu W.

Asian J Androl. 2016 Jul-Aug;18(4):533-42. doi: 10.4103/1008-682X.177120. Review.


New insights on the association between the prostate cancer and the small DNA tumour virus, BK polyomavirus.

Tognon M, Provenzano M.

J Transl Med. 2015 Dec 23;13:387. doi: 10.1186/s12967-015-0754-z.


Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer.

Nodouzi V, Nowroozi M, Hashemi M, Javadi G, Mahdian R.

Int Braz J Urol. 2015 Sep-Oct;41(5):898-905. doi: 10.1590/S1677-5538.IBJU.2014.0036.


The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients.

Babaei F, Ahmadi SA, Abiri R, Rezaei F, Naseri M, Mahmoudi M, Nategh R, Mokhtari Azad T.

Iran J Public Health. 2014 Apr;43(4):453-9.


Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.

Puto LA, Brognard J, Hunter T.

J Biol Chem. 2015 Jun 19;290(25):15406-20. doi: 10.1074/jbc.M115.658765. Epub 2015 Apr 22.


Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.

Minami A, Nakanishi A, Ogura Y, Kitagishi Y, Matsuda S.

Front Oncol. 2014 Nov 10;4:318. doi: 10.3389/fonc.2014.00318. eCollection 2014. Review.


Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer.

Poku RA, Amissah F, Duverna R, Aguilar BJ, Kiros GE, Lamango NS.

Ecancermedicalscience. 2014 Aug 28;8:459. doi: 10.3332/ecancer.2014.459. eCollection 2014.


Disruption of prostate epithelial differentiation pathways and prostate cancer development.

Frank SB, Miranti CK.

Front Oncol. 2013 Oct 31;3:273. doi: 10.3389/fonc.2013.00273. Review.


Reduced mitochondrial DNA content associates with poor prognosis of prostate cancer in African American men.

Koochekpour S, Marlowe T, Singh KK, Attwood K, Chandra D.

PLoS One. 2013 Sep 23;8(9):e74688. doi: 10.1371/journal.pone.0074688. eCollection 2013.


Genomic Rearrangements of PTEN in Prostate Cancer.

Phin S, Moore MW, Cotter PD.

Front Oncol. 2013 Sep 17;3:240. doi: 10.3389/fonc.2013.00240. Review.


Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era.

Chen J, Zhang D, Yan W, Yang D, Shen B.

Biomed Res Int. 2013;2013:901578. doi: 10.1155/2013/901578. Epub 2013 Jul 15. Review.


Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.

Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, Chang C.

Cancer Res. 2013 Sep 15;73(18):5633-46. doi: 10.1158/0008-5472.CAN-12-3228. Epub 2013 Jul 22.


Significant association of Glutathione S-transferase T1 null genotype with prostate cancer risk: a meta-analysis of 26,393 subjects.

Yang Q, Du J, Yao X.

PLoS One. 2013;8(1):e53700. doi: 10.1371/journal.pone.0053700. Epub 2013 Jan 24.


Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.

Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ.

Prostate. 2013 May;73(7):754-62. doi: 10.1002/pros.22619. Epub 2012 Nov 28.


p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 15;11(24):4579-88. doi: 10.4161/cc.22852. Epub 2012 Nov 27.

Supplemental Content

Support Center